In 590 unselected patients referred to a hematological department with suspected MN, excluding MPN, and without evidence of a nonmyleoid cause of symptoms, we identified a RUNX1 variant in 83 patients (14%); see Figure 1(a). This evidence concerns the gene RUNX1 and myeloproliferative neoplasm.